A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.
A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.
A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.
A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.
This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.
This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.
This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.
This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.
A US KOL provides insight into current and future therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.
A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.
A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.
A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.
This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.
This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.
This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.
This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study
A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.
This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.
A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.
A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.
A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.
A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.
A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.
Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.
Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.
An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.
An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine
An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.
An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.
In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.
In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.
Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views
This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.
In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD.
This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.
Datamonitor conducted a 5-question survey of 26 United States and 25 European (based in France, Germany, Italy, Spain and United Kingdom) neurologists involved in pain management to gauge current prescribing practices in prophylactic treatment of chronic migraine and potential future use of the calcitonin gene-related peptide (CGRP) receptor targeting monoclonal antibody (mAb) AMG 334 (AMGN) and CGRP targeting mAbs ALD403 (ALDR) and TEV-48125 (TEVA).
Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.
Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.
Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!